The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Eisai competitive analysis

Loading summary...

Latest patents of Eisai opposed by its competitors

Explore Eisai's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3861346
Jan 8, 2025Biomarkers For A Therapy Comprising A Sorafenib Compound1
EP3581183
Nov 29, 2023Tumor-Treating Pharmaceutical Composition1
EP3263106
Oct 25, 2023Method For Suppressing Bitterness Of Quinoline Derivative8
EP3524595
Aug 10, 2022High-Purity Quinoline Derivative And Method For Manufacturing Same10
EP3265122
May 4, 2022Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer4
EP3338779
Jun 30, 2021Tumor Therapeutic Agent1

Latest PTAB cases involving Eisai

Discover the latest PTAB cases involving Eisai, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 14, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Eisai

PGR2021-00047Feb 3, 2021EISAICRYSTAL PHARMACEUTICAL SUZHOUFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Eisai with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
EISAI - - 1 -
CRYSTAL PHARMACEUTICAL SUZHOU - 1 - 1